awmsg logo



anagrelide hydrochloride (Xagrid®)


Reference No. 23

Publication date:
06/05/2005


Appraisal information

anagrelide hydrochloride (Xagrid®) 0.5 mg capsule


Company: Shire Pharmaceuticals Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: 03/03/2005
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: Not available
Ministerial ratification: 06/05/2005

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

The Minister for Health and Social Services has endorsed AWMSG's recommendation to support the use of anagrelide within NHS Wales in accordance with its licensed indications and subject to the formation of a uniform pathway for the management of patients with essential thrombocythaemia throughout Wales. AWMSG would like haematologists as a professional group to monitor patients and address concerns with regard to long-term safety issues.
Final Appraisal Recommendation (FAR)
Download